Ligand Pharmaceuticals (LGND) is back in focus after its latest quarterly update, which combined higher royalty revenues and adjusted EPS with the planned XOMA acquisition and a contested termination of the Viking TR Beta licensing program.

The stock has eased in the very short term, with a 7 day share price return of down 4.9%. However, the 90 day share price return of 21.8% and the 1 year total shareholder return of 110.5% point to strong momentum as investors weigh the XOMA deal, royalty growth and the Viking TR Beta dispute against recent earnings volatility.

If you are looking beyond Ligand for other healthcare opportunities tied to AI and data driven drug development, this could be a good moment to scan 33 healthcare AI stocks

With the stock up 110.5% over the past year, yet still trading below analyst targets and intrinsic estimates, the key question is whether Ligand is undervalued on its expanding royalty base or if the market is already pricing in future growth.

Most Popular Narrative: 10.3% Undervalued

The most followed narrative on Ligand puts fair value at $246.70 compared with the latest close at $221.21, which frames the current debate around how much of the royalty story is already reflected in the price.

Strong revenue and earnings growth are expected as Ligand broadens its high margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long term cash flow predictability.

Want to see what sits behind that royalty growth story? The narrative leans on rising margins, firm revenue assumptions and a future earnings multiple that might surprise you.

Result: Fair Value of $246.70 (UNDERVALUED)

However, this depends on key risks, including pressure on royalty economics from drug pricing changes and the heavy reliance on a handful of partner assets actually delivering.

Another Angle On Value: P/E Tells A Different Story

While the narrative fair value and DCF work suggest upside, the simple P/E check is less generous. Ligand trades on a 28.9x P/E, which is higher than both the US Pharmaceuticals industry at 15.6x and the fair ratio of 18x. On this lens the stock screens expensive and raises the question of how much optimism is already priced in.

To see how these earnings multiples stack up in more detail, including peer comparisons and the fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between rich P/E multiples and an undervalued narrative, it makes sense to act quickly and stress test the numbers yourself. To see what the optimism is built on, take a closer look at the 4 key rewards

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities that could fit your goals even better, so broaden your watchlist with a few targeted screens.

• Spot potential turnaround candidates early by scanning 28 elite penny stocks with strong financials before wider attention arrives.
• Zero in on quality at a reasonable price by filtering for 47 high quality undervalued stocks that pair fundamentals with attractive valuations.
• Prioritise resilience by reviewing solid balance sheet and fundamentals stocks screener (45 results) that aim for stronger financial footing when conditions get tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.